Journal article
Bleeding and thrombotic risk in pregnant women with Fontan physiology
A Girnius, D Zentner, AM Valente, PG Pieper, KE Economy, M Ladouceur, JW Roos-Hesselink, C Warshak, SL Partington, Z Gao, N Ollberding, M Faust, S Girnius, H Kaemmerer, N Nagdyman, S Cohen, M Canobbio, T Akagi, J Grewal, E Bradley Show all
Heart | BMJ PUBLISHING GROUP | Published : 2021
Abstract
Background/objectives Pregnancy may potentiate the inherent hypercoagulability of the Fontan circulation, thereby amplifying adverse events. This study sought to evaluate thrombosis and bleeding risk in pregnant women with a Fontan. Methods We performed a retrospective observational cohort study across 13 international centres and recorded data on thrombotic and bleeding events, antithrombotic therapies and pre-pregnancy thrombotic risk factors. Results We analysed 84 women with Fontan physiology undergoing 108 pregnancies, average gestation 33±5 weeks. The most common antithrombotic therapy in pregnancy was aspirin (ASA, 47 pregnancies (43.5%)). Heparin (unfractionated (UFH) or low molecula..
View full abstractGrants
Funding Acknowledgements
Sheila Drakeley (Boston Children's Hospital), and the International Society of Adult Congenital Heart Disease (ISACHD, www.isachd.org) and the AARCC under whose auspices this study was supported. EO currently holds the Bitove Family Professorship of Adult Congenital Heart Disease. Dr Elisa Bradley holds a grant with the following grant number:K08HL148701